These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 10622226)

  • 41. Recent advances with topotecan in the treatment of lung cancer.
    O'Brien M; Eckardt J; Ramlau R
    Oncologist; 2007 Oct; 12(10):1194-204. PubMed ID: 17962613
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.
    Rodriguez M; Rose PG
    Gynecol Oncol; 2001 Nov; 83(2):257-62. PubMed ID: 11606080
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase II study of metronomic oral topotecan for recurrent childhood brain tumors.
    Minturn JE; Janss AJ; Fisher PG; Allen JC; Patti R; Phillips PC; Belasco JB
    Pediatr Blood Cancer; 2011 Jan; 56(1):39-44. PubMed ID: 21108437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Absolute bioavailability studies of a new oral topotecan formulation in Chinese patients using UHPLC-MS/MS.
    Li N; Han X; Yang J; Gui L; Song Y; Du P; Shi Y
    J Pharm Biomed Anal; 2013 Mar; 76():252-6. PubMed ID: 23354352
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts.
    De Cesare M; Zunino F; Pace S; Pisano C; Pratesi G
    Eur J Cancer; 2000 Aug; 36(12):1558-64. PubMed ID: 10930804
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Topotecan: Incorporating It Into the Treatment of Solid Tumors.
    Burris HA
    Oncologist; 1998; 3(1):1-3. PubMed ID: 10388078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Topotecan: what dose, what schedule, what route?
    O'Reilly S
    Clin Cancer Res; 1999 Jan; 5(1):3-5. PubMed ID: 9918195
    [No Abstract]   [Full Text] [Related]  

  • 48. A pharmacokinetic evaluation of topotecan as a cervical cancer therapy.
    Musa F; Blank S; Muggia F
    Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):215-24. PubMed ID: 23320990
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog.
    Davies BE; Minthorn EA; Dennis MJ; Rosing H; Beijnen JH
    Pharm Res; 1997 Oct; 14(10):1461-5. PubMed ID: 9358562
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.
    Shah DK; Balthasar JP
    Int J Pharm; 2014 Apr; 465(1-2):228-38. PubMed ID: 24508555
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of oral cytotoxic and cytostatic drugs in cancer treatment.
    Sparreboom A; de Jonge MJ; Verweij J
    Eur J Cancer; 2002 Jan; 38(1):18-22. PubMed ID: 11750835
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tracking the cell cycle origins for escape from topotecan action by breast cancer cells.
    Feeney GP; Errington RJ; Wiltshire M; Marquez N; Chappell SC; Smith PJ
    Br J Cancer; 2003 Apr; 88(8):1310-7. PubMed ID: 12698201
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of Topotecan in Non-Small Cell Lung Cancer: A Review of Literature.
    Vennepureddy A; Atallah JP; Terjanian T
    World J Oncol; 2015 Oct; 6(5):429-436. PubMed ID: 28983343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice.
    Chen J; Lu Q; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2007 Dec; 34(6):829-47. PubMed ID: 17885736
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
    Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Review of phase I clinical studies with topotecan.
    Rowinsky EK; Verweij J
    Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-3-S20-10. PubMed ID: 9425956
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
    Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
    Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
    Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
    Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The evolving role of oral topotecan.
    Burris HA
    Semin Hematol; 1999 Oct; 36(4 Suppl 8):26-32. PubMed ID: 10622226
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.